Journal
NATURE REVIEWS NEUROLOGY
Volume 15, Issue 7, Pages 365-366Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41582-019-0205-1
Keywords
-
Categories
Ask authors/readers for more resources
In the march towards disease-modifying treatments for Alzheimer disease, immunotherapy with antibodies against amyloid-beta protein is furthest along in human trials. The news that Biogen's aducanumab showed no cognitive benefit in phase III trials requires careful analysis of what went wrong and how to position anti-amyloid agents among other therapeutic approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
